You are here:

Archived: inhaled mannitol (Bronchitol)

Advice

following a full submission:

mannitol (Bronchitol®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.

In two phase III clinical studies in patients with CF, inhaled mannitol was superior to a control treatment (a sub-therapeutic dose of inhaled mannitol) measured by absolute change in forced expiratory volume in one second (FEV1) over 26 weeks.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: inhaled mannitol (Bronchitol)
SMC Drug ID: 837/13
Manufacturer: Pharmaxis Pharmaceuticals Ltd
Indication: For cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.
BNF Category:
Sub Category: 3.7 Mucolytics
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 11 February 2013

Current Advice

Resubmission 9 December 2013

Back